Hyperlipidemia – The Hidden Link between Psoriasis and Cardiovascular Disease

Ahmed Naveed Malik; Nadia Iftikhar; Muhammad Abbas; Muhammad  Anjum; Hunain  Habib; Azhar Hosain  Minhas

doi:10.51253/pafmj.v76iSUPPL-2.11649

Authors

Ahmed Naveed Malik Department of Dermatology, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Nadia Iftikhar Department of Dermatology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Muhammad Abbas Department of Dermatology, Combined Military Hospital Sialkot/National University of Medical Sciences (NUMS) Pakistan
Muhammad Anjum Department of Dermatology, Combined Military Hospital Kohat/National University of Medical Sciences (NUMS) Pakistan
Hunain Habib Department of Pathology, Fazaia Medical College, Air University, Islamabad Pakistan
Azhar Hosain Minhas Department of Dermatology, Combined Military Hospital Kharian/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-2.11649

Keywords:

Cardiovascular Disease (CVD), Dyslipidemia, Lipid Profile, Psoriasis

Abstract

Objective: To study the prevalence of dyslipidemia in patients of psoriasis and compare it with that of matched controls.

Study Design: Quasi-experimental study.

Place and Duration of Study: Department of Dermatology, Pak Emirates Military Hospital (PEMH), Rawalpindi Pakistan, from Mar to Jun 2023.

Methodology: The study enrolled 40 patients suffering from psoriasis and 40 healthy individuals considered as controls. Fasting Serum Total Cholesterol (TC), Serum Triglycerides (TG), Serum High Density Lipoprotein Cholesterol (HDL-C) and Serum Low Density Lipoprotein Cholesterol (LDL-C) of all the participants in both groups were measured and the results were compared and analyzed.

Results: Out of the 40 patients of the psoriasis group, 27(67.5%) had at least one lipid abnormality while in the control group only 7(17.5%) individuals had aberrant fasting lipid profile. When both the groups were compared, there were significant differences in mean fasting serum concentrations of TG and HDL (p=0.001, p=0.001 respectively) as well as fasting serum concentrations of TC and LDL (p=0.001, p=0.001 respectively).

Conclusion: Fasting lipid concentration was significantly abnormal for Serum Total Cholesterol (TC), Serum Triglycerides (TG), Serum High Density Lipoprotein Cholesterol (HDL-C) and Serum Low Density Lipoprotein Cholesterol (LDL-C), indicating a trend toward dyslipidemia in psoriasis patients.

Downloads

Download data is not yet available.

References

1. Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol 2020; 156(4): 421–429.

https://doi.org/10.1001/jamadermatol.2020.0024

2. Snekvik I, Nilsen T, Romundstad P, Saunes M. Psoriasis and cardiovascular disease risk factors: the HUNT Study, Norway. J Eur Acad Dermatol Venereol 2018; 32(5): 776–782.

https://doi.org/10.1111/jdv.14835

3. Manolis AA, Manolis TA, Melita H, Manolis AS. Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol 2019; 38(1): 33–54. https://doi.org/10.1080/08830185.2018.1539084

4. Sanda G, Belur A, Teague H, Mehta NN. Emerging associations between neutrophils, atherosclerosis, and psoriasis. Curr Atheroscler Rep 2017; 19(12): 53.

https://doi.org/10.1007/s11883-017-0692-8

5. Miao C, Li J, Li Y, Zhang X. Obesity and dyslipidemia in patients with psoriasis: a case-control study. Medicine (Baltimore) 2019; 98(31): e16323.

https://doi.org/10.1097/md.0000000000016323

6. Cannavò SP, Riso G, Casciaro M, Di Salvo E, Gangemi S. Oxidative stress involvement in psoriasis: a systematic review. Free Radic Res 2019; 53(8): 829–840.

https://doi.org/10.1080/10715762.2019.1648800

7. Kim HN, Han K, Song SW, Lee JH. Hypertension and risk of psoriasis incidence: an 11-year nationwide population-based cohort study. PLoS One 2018; 13(8): e0202854.

https://doi.org/10.1371/journal.pone.0202854

8. Duan X, Liu J, Mu Y, Liu T, Chen Y, Yu R, et al. A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates. Medicine 2020; 99(9): e19303.

https://doi.org/10.1097/md.0000000000019303

9. Mamizadeh M, Tardeh Z, Azami M. The association between psoriasis and diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Syndr 2019; 13(2): 1405–1412.

https://doi.org/10.1016/j.dsx.2019.01.009

10. Levi SS, Ramot Y. Gender differences in psoriasis. Gender and dermatology 2018; 63–81.

https://doi.org/10.1007/978-3-030-49285-4_3

11. Salunke AS, Nagargoje MV, Belgaumkar VA, Tolat SN, Chavan RB. Association of metabolic syndrome in chronic plaque psoriasis patients and their correlation with disease severity, duration and age: a case control study from Western Maharashtra. J Clin Diagn Res 2017; 11(8): WC06–9.

https://doi.org/10.7860/jcdr/2017/24390.10348

12. Stein R, Ferrari F, Scolari F. Genetics, dyslipidemia, and cardiovascular disease: new insights. Curr Cardiol Rep 2019; 21(8): 68. https://doi.org/10.1007/s11886-019-1161-5

13. Kafle M, Gyawlee M, Amatya A, Kayastha BMM, Upadhyaya S. Dyslipidemia in psoriasis: a case-controlled study. Nepal J Dermatol Venereol Leprol 2021; 19(2): 39–43.

https://doi.org/10.3126/njdvl.v19i2.36809

14. Mirza UA, Hussain I, Iftikhar U. Association of dyslipidemia with psoriasis. J Pak Assoc Dermatol 2019; 28(4): 532–539.

15. Abidoye O, Lediju O, Zahid Z, Naseeruddin R, Patel P, Lal M, et al. Development of dyslipidemia in psoriasis patients. Eur J Biomed Pharm Sci 2017; 4(9): 746–748.

16. Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol 2020; 11: 117.

https://doi.org/10.3389/fphar.2020.00117

17. Kimball AB, Szapary P, Mrowietz U, Reich K, Langley RG, You Y, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol 2012; 67(1): 76–85.

https://doi.org/10.1016/j.jaad.2011.06.035

18. Girona J, Amigó N, Ibarretxe D, Plana N, Rodríguez-Borjabad C, Heras M, et al. HDL triglycerides: a new marker of metabolic and cardiovascular risk. Int J Mol Sci 2019; 20(13): 3151.

https://doi.org/10.3390/ijms20133151

19. Pappa E, Elisaf MS, Kostara C, Bairaktari E, Tsimihodimos VK. Cardioprotective properties of HDL: structural and functional considerations. Curr Med Chem 2020; 27(18): 2964–2978.

https://doi.org/10.2174/0929867326666190201142321

20. Fotakis P, Kothari V, Thomas DG, Westerterp M, Molusky MM, Altin E, et al. Anti-inflammatory effects of HDL (high-density lipoprotein) in macrophages predominate over proinflammatory effects in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2019; 39(12): e253–272.

https://doi.org/10.1161/atvbaha.119.313253

21. Luo L, Guo Y, Chen L, Zhu J, Li C. Crosstalk between cholesterol metabolism and psoriatic inflammation. Front Immunol 2023; 14: 1124786. https://doi.org/10.3389/fimmu.2023.1124786

22. Xepapadaki E, Zvintzou E, Kalogeropoulou C, Filou S, Kypreos KE. The antioxidant function of HDL in atherosclerosis. Angiology 2020; 71(2): 112–121.

https://doi.org/10.1177/0003319719854609

23. Nussbaum L, Chen Y, Ogg G. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br J Dermatol 2021; 184(1): 14–24. https://doi.org/10.1111/bjd.19380

24. Lacy M, Atzler D, Liu R, de Winther M, Weber C, Lutgens E. Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis. Pharmacol Ther 2019; 193: 50–62.

https://doi.org/10.1016/j.pharmthera.2018.08.012

25. Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis 2020; 19(1): 42.

https://doi.org/10.1186/s12944-020-01204-y